Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: SGLT2 inhibitors


Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK

September 25th 2017

This analysis suggests that, in the UK, canagliflozin 300 mg provides the best value for money among all SGLT2 inhibitors in terms of achieving HbA1c <7.0% when used as part of triple therapy with metformin plus sulfonylurea (Diabetes Therapy)

Categories: Medication, News
Tags: canagliflozin, SGLT2 inhibitors, Type 2 Diabetes, UK

Categories: Medication
Tags: canagliflozin, SGLT2 inhibitors, Type 2 Diabetes, UK

Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis

September 11th 2017

In this real-life analysis, the rate of hospitalizations for heart failure was significantly lower for patients initiating an SGLT2 compared with a DPP4 medication, specifically among older patients and those with diabetes complication (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: DPP4, oral antidiabetic, SGLT2 inhibitors

Categories: Cardiovascular
Tags: DPP4, oral antidiabetic, SGLT2 inhibitors

Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study

September 9th 2017

Our study is expected to provide clinical data that will be helpful in the prevention of diabetic atherosclerosis and subsequent cardiovascular and cerebrovascular disease (Diabetes Therapy)

Categories: News, Prevention
Tags: atherosclerosis, SGLT2 inhibitors

Categories: Prevention
Tags: atherosclerosis, SGLT2 inhibitors

Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis

August 31st 2017

Our findings do not suggest an increased risk of AKI associated with SGLT2 inhibitor use in patients with T2D in two large health systems (Diabetes Care)

Categories: Nephropathy, News
Tags: SGLT2 inhibitors

Categories: Nephropathy
Tags: SGLT2 inhibitors

Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring

August 19th 2017

The results showed that the SGLT2 inhibitors lower blood glucose from 2 h after the first dose and improve blood glucose variation by week 1 after start of the treatment. Furthermore, SGLT2 inhibitors did not alter the incidence of hypoglycemic episodes at week 1, suggesting that SGLT2 protects against severe hypoglycemia by inhibiting urinary glucose excretion  (Diabetology & Metabolic Syndrome)

Categories: Medication, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: SGLT2 inhibitors, Type 2 Diabetes

Glucose-lowering drugs: balancing risks and benefits

August 10th 2017

Yet more evidence in support of a class effect of SGLT2 inhibitors  (The Lancet Diabetes & Endocrinology)

Categories: Management, News
Tags: SGLT2 inhibitors

Categories: Management
Tags: SGLT2 inhibitors

Sodium-Glucose Cotransporter-2 Inhibition Improves Incretin Sensitivity of Pancreatic β-cells in Patients with Type 2 Diabetes

August 8th 2017

Dapagliflozin improved β-cell responses to incretin hormones as well as glucose during the hyperglycemic clamp in patients with inadequately controlled T2DM (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: beta cells, incretin, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: beta cells, incretin, SGLT2 inhibitors, Type 2 Diabetes

Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring

August 5th 2017

The results showed that the SGLT2 inhibitors lower blood glucose from 2 h after the first dose and improve blood glucose variation by week 1 after start of the treatment. Furthermore, SGLT2 inhibitors did not alter the incidence of hypoglycemic episodes at week 1, suggesting that SGLT2 protects against severe hypoglycemia by inhibiting urinary glucose excretion (Diabetology & Metabolic Syndrome)

Categories: News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories:
Tags: SGLT2 inhibitors, Type 2 Diabetes

Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program

June 15th 2017

Similar to existing evidence, we found a higher risk of genital infection associated with SGLT2 inhibitors (primarily dapagliflozin) but no increased risk of UTIs compared to DPP-4 use (Diabetes Research and Clinical Practice)

Categories: Medication, News
Tags: dapagliflozin, SGLT2 inhibitors

Categories: Medication
Tags: dapagliflozin, SGLT2 inhibitors

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

May 17th 2017

All the researches, mentioned in this paper, demonstrating the SGLT2 inhibitors with their novel mechanism and associated benefits on glucose-lowering, renoprotection, body weight, CV safety, etc. have proved to be promising choices either as monotherapy or as combination therapy for patients with DKD (Cardiovascular Diabetology)

Categories: Medication, News
Tags: CKD, SGLT2 inhibitors

Categories: Medication
Tags: CKD, SGLT2 inhibitors

Lack of Evidence for a Harmful Effect of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Fracture Risk among Type 2 Diabetes Patients

July 13th 2016

Our meta-analysis based on available RCT data does not support the harm effect of SGLT2 inhibitors on fracture, although future safety monitoring from RCT and real-world data with detailed information on bone health is warranted (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: fracture, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: fracture, SGLT2 inhibitors, Type 2 Diabetes

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis

March 19th 2016

These data suggest net protection of SGLT2 inhibitors against cardiovascular outcomes and death (The Lancet Diabetes & Endocrinology)

Categories: Medication, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: SGLT2 inhibitors, Type 2 Diabetes

SGLT2 inhibitors: PRAC makes recommendations to minimise risk of diabetic ketoacidosis

February 12th 2016

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has finalised a review of SGLT2 inhibitors (a class of type 2 diabetes medicines) and has made recommendations to minimise the risk of diabetic ketoacidosis (EMA)

Categories: Medication, News
Tags: Ketoacidosis, SGLT2 inhibitors

Categories: Medication
Tags: Ketoacidosis, SGLT2 inhibitors

Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to insulin degludec/liraglutide

November 3rd 2015

Although the effects differ with each individual class of therapy, clinical trials have shown that adding a glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor or sodium-glucose co-transporter-2 inhibitor to insulin regimens can offer a significant reduction in HbA1c without substantially increasing hypoglycaemia risk, or weight (Diabetic Medicine)

Categories: Medication, News
Tags: incretin, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: incretin, SGLT2 inhibitors, Type 2 Diabetes
  • « Previous Page
  • 1
  • 2
  • 3

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

MSDNapp DiabetesNovo NordiskAstraZeneca

Silver Sponsors

AmgenWelsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes CareSanofi Diabetes

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin cancer CGM closed-loop dapagliflozin DPP4 Empagliflozin exenatide exercise GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NICE OGTT pioglitazone pregnancy retinopathy RYGB semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2019 Glycosmedia Partnership